Footnotes: 2008 Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) annual report

Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)

Footnotes

Footnote note1

Centre for Foodborne, Environmental and Zoonotic Infectious Diseases

Return to footnotenote1 Referrer

Footnote note2

Laboratory for Foodborne Zoonoses

Return to footnotenote2 Referrer

Footnote note3

National Microbiology Laboratory

Return to footnotenote3 Referrer

Footnote note4

Escherichia coli were identified by use of biochemical tests. No attempt was made to distinguish pathogenic strains of E. coli from non-pathogenic strains.

Return to footnotenote4 Referrer

Footnote note5

The MIC is the lowest concentration of an antimicrobial that inhibits visible bacterial growth after incubation.

Return to footnotenote5 Referrer

Footnote note6

Ceftiofur is licensed for use in animals only. Resistance to ceftiofur is generally detected in combination with resistance to amoxicillin-clavulanic acid, cefoxitin, ampicillin and ceftriaxone (A2C-AMP-CRO resistance pattern).

Return to footnotenote6 Referrer

Footnote note7

World Health Organization. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses ( ATC/ DDD). Available at: www.who.int/classifications/atcddd/en/ . Accessed October 2010.

Return to footnotenote7 Referrer

Footnote note8

The current CLSI resistance breakpoint for this antimicrobial and the one adopted in this report is ≥ 4 μg/mL. However, the Danish Integrated Antimicrobial Resistance Monitoring and Research Program ( DANMAP) has used a resistance breakpoint of ≥ 0.125 μg/mL for both Salmonella spp. and indicator E. coli since 2004 and for pathogenic E. coli since 2006. The DANMAP also introduced European Committee on Antimicrobial Susceptibility Testing epidemiological cutoff values in their 2007 report. Because of the clinical importance of ciprofloxacin and a desire to present results in a format comparable with those of DANMAP, the term "reduced susceptibility" is used for ciprofloxacin MICs from 0.125 to 2 μg/mL. To obtain resistance estimates comparable to those from DANMAP, the percentage of E. coli and Salmonella isolates in this report with reduced susceptibility must be added to the percentage of isolates resistant to ciprofloxacin.

Return to footnotenote8 Referrer

Footnote note9

Public Health Agency of Canada. Salmonella Heidelburg Ceftiofur-Related Resistance in Human and Retail Chicken Isolates. Available at: www.phac-aspc.gc.ca/cipars-picra/heidelberg/heidelberg-eng.php. Accessed October 2010.

Return to footnotenote9 Referrer

Footnote note10

"Fluoroquinolone-susceptible strains of Salmonella that test resistant to nalidixic acid may be associated with clinical failure or delayed response in fluoroquinolone-treated patients with extra-intestinal salmonellosis. Extra-intestinal isolates of Salmonella should also be tested for resistance to nalidixic acid. For isolates that test susceptible to fluoroquinolones and resistant to nalidixic acid, the physician should be informed that the isolate may not be eradicated by fluoroquinolone treatment." (CLSI M100-S16).

Return to footnotenote10 Referrer

Footnote note11

Public Health Agency of Canada, Salmonella paratyphi Material Safety Data Sheet. Available at: www.phac-aspc.gc.ca/msds-ftss/msds133e-eng.php. Accessed November 2010.

Return to footnotenote11 Referrer

Footnote note12

Does not include S. Paratyphi B var. L (+) tartrate+, formerly called S. Paratyphi var. Java. The biotype of S. Paratyphi B included here is tartrate (-) and is associated with more severe, typhoid-like fever. Salmonella Paratyphi B var. L (+) tartrate+ is commonly associated with gastroenteritis. Because animals can be a source of this serovar, it is included under "Other Serovars."

Return to footnotenote12 Referrer

Footnote note13

2004 and 2006 were selected as years of comparison for ceftiofur and ampicillin resistance because of a change in ceftiofur use practices by Québec chicken hatcheries in early 2005 and in 2006 (start and end of the voluntary period of withdrawal).

Return to footnotenote13 Referrer

Footnote note14

Return to footnotenote14 Referrer

Footnote note15

Distribution of Salmonella isolates across provinces is presented in , .

Return to footnotenote15 Referrer

Footnote note16

Return to footnotenote16 Referrer

Footnote note17

Return to footnotenote17 Referrer

Footnote note18

Distribution of Salmonella isolates across provinces is presented in , .

Return to footnotenote18 Referrer

Footnote note19

Isolates recovered from retail chicken in the Maritimes region underwent antimicrobial susceptibility testing, but results are not presented in this report because of concerns regarding harmonization of laboratory methods for 2008 only.

Return to footnotenote19 Referrer

Footnote note20

Isolates recovered from retail chicken in the Maritimes region underwent antimicrobial susceptibility testing but results are not presented in this report because of concerns surrounding harmonization of laboratory methods for 2008 only.

Return to footnotenote20 Referrer

Footnote note21

The percentages provided in the text and in the figures and tables were adjusted to account for clustering within herds, whereas proportions represent unadjusted values (see Appendix A).

Return to footnotenote21 Referrer

Footnote note22

Because few isolates were recovered in 2003 (2%, 2/125), testing was stopped in 2004 and 2005. However, given increasing concern and interest associated with Salmonella in pork, testing was reinitiated in 2006. In 2007, a new method of isolate recovery was implemented for all retail meat samples. For a summary of recovery by year and province, see , .

Return to footnotenote22 Referrer

Footnote note23

Because of the low prevalence of Salmonella detected in pork, antimicrobial susceptibility results for the few isolates recovered each year are not presented on an annual basis. Rather, 6 years of results have been pooled together and are presented here.

Return to footnotenote23 Referrer

Footnote note24

Distribution of Salmonella isolates across provinces is presented in , .

Return to footnotenote24 Referrer

Footnote note25

The number of generic E. coli isolates recovered through Farm Surveillance was much higher than through other surveillance components. The reason for collecting a larger number of isolates in Farm Surveillance is to ensure adequate power to investigate the association between antimicrobial resistance and antimicrobial use. A large number of isolates facilitates the identification of statistically significant small changes (such as plus or minus 0.5%), particularly when the prevalence of resistance is around 1%. Although significant, the increase in ceftiofur resistance between 2007 and 2008 (from less than 1% to 1%) may simply reflect natural variation from year to year.

Return to footnotenote25 Referrer

Footnote note26

The percentages provided in the text and in the figures and tables were adjusted to account for clustering within herds, whereas proportions represent unadjusted values (see Appendix A).

Return to footnotenote26 Referrer

Footnote note28

Distribution of Salmonella isolates across provinces is presented in , .

Return to footnotenote28 Referrer

Footnote note30

Defined daily dosages were computed from data on dispensed prescriptions for orally administered antimicrobials. However, an unknown proportion of the drugs sold by retail pharmacies is not consumed. To improve text clarity, the word "consumption" is used, although the total DDD estimates presented slightly overestimate true consumption.

Return to footnotenote30 Referrer

Footnote note31

European Surveillance of Antimicrobial Consumption. ESAC Yearbook 2007. Available at: www.esac.ua.ac.be/main.aspx?c=*ESAC2&n=50036 . Accessed March 2010. Note: Data were available for Malta but were not included in the comparisons because the numbers were too low (i.e. 1.7 DDDs/1,000 inhabitants).

Return to footnotenote31 Referrer

Footnote note32

Other animal demographic information is presented in and , .

Return to footnotenote32 Referrer

Footnote note33

See: www.phac-aspc.gc.ca/cipars-picra/2006-eng.php. Accessed December 2010.

Return to footnotenote33 Referrer

Footnote note34

Division of AgLine/TI Communications Ltd. See: www.impactvet.com. Accessed August 2009.

Return to footnotenote34 Referrer

Footnote note35

For ceftriaxone, analysis was done based on a resistance breakpoint of 64 µg/mL.

Return to footnotenote35 Referrer

Footnote note36

Version April, 2009. Available at: www.hc-sc.gc.ca/dhp-mps/consultation/vet/consultations/amr_ram_hum-med-rev-eng.php. Accessed February 2010.

Return to footnotenote36 Referrer

Footnote note37

Report of the 2001 Canadian Laboratory Study, National Studies on Acute Gastrointestinal Illness, Division of Enteric, Foodborne and Waterborne Diseases, 2002.

Return to footnotenote37 Referrer

Footnote note38

Agriculture and Agri-Food Canada. Red meat market information. Available at: www.agr.gc.ca/redmeat-vianderouge/index_eng.htm . Accessed November 2010.

Return to footnotenote38 Referrer

Footnote note39

When legs with skin on were not available, wings with skin on or other cuts of chicken were purchased instead.

Return to footnotenote39 Referrer

Footnote note40

At 1 store in each division, the beef sample was not collected to minimize over-sampling of this commodity.

Return to footnotenote40 Referrer

Footnote note41

When legs with skin on were not available, wings with skin on or other cuts were purchased instead.

Return to footnotenote41 Referrer

Footnote note42

Office Internationale des Épizooties, OIÉ; All World Organisation for Animal Health, Reference Laboratory for Salmonellosis, Guelph, Ontario.

Return to footnotenote42 Referrer

Footnote note43

World Health Organization Collaborating Center for Drug Statistics Methodology. Available at: www.whocc.no/atcddd. Accessed October 2010.

Return to footnotenote43 Referrer

Footnote note44

Veterinary Drugs Directorate. Categorization of Antimicrobial Drugs Based on Importance in Human Medicine. Version of April 2009. See: www.hc-sc.gc.ca/dhp-mps/consultation/vet/consultations/amr_ram_hum-med_e.html. Accessed October 2010.

Return to footnotenote44 Referrer

Page details

Date modified:: 2011-10-26

Language selection

Search

Footnotes: 2008 Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) annual report

Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)

Footnotes

Page details